131 related articles for article (PubMed ID: 27799390)
1. Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases.
Ruano-Ravina A; Torres-Durán M; Kelsey KT; Parente-Lamelas I; Leiro-Fernández V; Abdulkader I; Abal-Arca J; Montero-Martínez C; Vidal-García I; Amenedo M; Castro-Añón O; Golpe-Gómez A; González-Barcala J; Martínez C; Guzmán-Taveras R; Provencio M; Mejuto-Martí MJ; Fernández-Villar A; Barros-Dios JM
Eur Respir J; 2016 Nov; 48(5):1462-1470. PubMed ID: 27799390
[TBL] [Abstract][Full Text] [Related]
2. Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.
Soo RA; Kubo A; Ando M; Kawaguchi T; Ahn MJ; Ou SI
Clin Lung Cancer; 2017 Sep; 18(5):535-542. PubMed ID: 28433570
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
4. Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study.
Torres-Durán M; Ruano-Ravina A; Kelsey KT; Parente-Lamelas I; Leiro-Fernández V; Abdulkader I; Provencio M; Abal-Arca J; Castro-Añón O; Montero-Martínez C; Vidal-García I; Amenedo M; Golpe-Gómez A; Martínez C; Guzmán-Taveras R; Mejuto-Martí MJ; Fernández-Villar A; Barros-Dios JM
Cancer Lett; 2017 Dec; 411():130-135. PubMed ID: 28987389
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer in never-smokers: a case-control study in a radon-prone area (Galicia, Spain).
Torres-Durán M; Ruano-Ravina A; Parente-Lamelas I; Leiro-Fernández V; Abal-Arca J; Montero-Martínez C; Pena-Álvarez C; González-Barcala FJ; Castro-Añón O; Golpe-Gómez A; Martínez C; Mejuto-Martí MJ; Fernández-Villar A; Barros-Dios JM
Eur Respir J; 2014 Oct; 44(4):994-1001. PubMed ID: 25034571
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
Lee B; Lee T; Lee SH; Choi YL; Han J
Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
8. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
[TBL] [Abstract][Full Text] [Related]
10. Residential radon in Galicia: a cross-sectional study in a radon-prone area.
Lorenzo-González M; Ruano-Ravina A; Peón J; Piñeiro M; Barros-Dios JM
J Radiol Prot; 2017 Sep; 37(3):728-741. PubMed ID: 28608782
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
13. Exposure to residential radon and lung cancer in never-smokers: the preliminary results of the LCRINS study.
Ruano-Ravina A; Prini-Guadalupe L; Barros-Dios JM; Abal-Arca J; Leiro-Fernández V; González-Silva AI; Golpe-Gómez A; González-Barcala FJ; Pena C; Montero-Martínez C; Martínez-González C; Mejuto-Martí MJ; Veres-Racamonde A
Arch Bronconeumol; 2012 Nov; 48(11):405-9. PubMed ID: 22818755
[TBL] [Abstract][Full Text] [Related]
14. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
[TBL] [Abstract][Full Text] [Related]
16. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Lee SH; Kim SJ; Yoon HK; Kim TJ; Lee KY
PLoS One; 2015; 10(11):e0142306. PubMed ID: 26555338
[TBL] [Abstract][Full Text] [Related]
17. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.
Esteban E; Majem M; Martinez Aguillo M; Martinez Banaclocha N; Dómine M; Gómez Aldaravi L; Juan O; Cajal R; Gonzalez Arenas MC; Provencio M
Cancer Epidemiol; 2015 Jun; 39(3):291-7. PubMed ID: 25766256
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
20. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
